ChatGPT in Drug Discovery: A Case Study on Anti-Cocaine Addiction Drug Development with Chatbots

TL;DR

This paper demonstrates how ChatGPT can be used as an innovative AI tool to assist researchers in designing and developing anti-cocaine addiction drugs, highlighting a new collaborative approach in drug discovery.

Contribution

It introduces a novel application of ChatGPT as a virtual guide in drug discovery, specifically for generating drug-like molecules targeting cocaine addiction.

Findings

ChatGPT effectively guides the design of drug-like molecules.

AI-human collaboration enhances drug development strategies.

The approach accelerates the identification of potential drug candidates.

Abstract

The birth of ChatGPT, a cutting-edge language model-based chatbot developed by OpenAI, ushered in a new era in AI. However, due to potential pitfalls, its role in rigorous scientific research is not clear yet. This paper vividly showcases its innovative application within the field of drug discovery. Focused specifically on developing anti-cocaine addiction drugs, the study employs GPT-4 as a virtual guide, offering strategic and methodological insights to researchers working on generative models for drug candidates. The primary objective is to generate optimal drug-like molecules with desired properties. By leveraging the capabilities of ChatGPT, the study introduces a novel approach to the drug discovery process. This symbiotic partnership between AI and researchers transforms how drug development is approached. Chatbots become facilitators, steering researchers towards innovative methodologies and productive paths for creating effective drug candidates. This research sheds light on the collaborative synergy between human expertise and AI assistance, wherein ChatGPT's cognitive abilities enhance the design and development of potential pharmaceutical solutions. This paper not only explores the integration of advanced AI in drug discovery but also reimagines the landscape by advocating for AI-powered chatbots as trailblazers in revolutionizing therapeutic innovation.